Christine Posted August 23, 2007 Share Posted August 23, 2007 http://www.forbes.com/feeds/afx/2007/08 ... tner=email PARIS (Thomson Financial) - Sanofi-Aventis and Regeneron Pharmaceuticals Inc have begun two phase 3 trials of a jointly-developed drug on patients with prostate cancer and non-small cell lung cancer. Aflibercept is an anti-angiogenic agent targeting Vascular Endothelial Growth Factor (VEGF). It is designed to be used in conjunction with chemotherapy regimens. The two trials will be double-blind and placebo-controlled, Regeneron said. Sanofi-Aventis will provide an update of the broad-based clinical development programme planned for the drug as well as further details on the trials at its research and development day on September 17. Sanofi-Aventis said in June it would start seeking regulatory approval as early as next year to market the drug. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.